

PHTS Guideline Summary

This guideline has been drawn from the best available evidence and the consensus of experts in this area and it is regularly updated to reflect changes in evidence.

The expectation is that clinicians will follow this guideline unless there is a compelling clinical reason specific to an individual patient not to.



**European
Reference
Network**

for rare or low prevalence
complex diseases

 **Network**
Genetic Tumour Risk
Syndromes (ERN GENTURIS)



www.genturis.eu

	Surveillance	Interval	From Age	Evidence
Breast cancer	MRI	Yearly	30	Strong
	Mammography	Every 2 yrs.	40	Moderate
	Risk reducing surgery offered	-	-	Moderate
Thyroid cancer	Ultrasound	Yearly	18*	Strong
Renal cancer	Ultrasound	Every 2 yrs.	40	Moderate
Colorectal cancer	Baseline colonoscopy	-	35-40	Moderate
Melanoma	Baseline skin examination**	-	30	Weak
Endometrial cancer***	Not recommended	-	-	Weak

*Moderate evidence for age of commencement of surveillance. ** Consider further surveillance as required. ***Consider surveillance as part of clinical trial.

Cancer Surveillance Guideline

Individual with PTEN hamartoma tumour syndrome (PHTS).

This guideline has been drawn from the best available evidence and the consensus of experts in this area and it is regularly updated to reflect changes in evidence.

The expectation is that clinicians will follow this guideline, unless there is a compelling clinical reason specific to an individual patient not to.



**European
Reference
Network**

for rare or low prevalence
complex diseases

 **Network**
Genetic Tumour Risk
Syndromes (ERN GENTURIS)



www.genturis.eu